Healthy Adults Needed for Beryllium Disease Study Request More Information Trial Objective Chronic beryllium disease (CBD) is caused by inhaling beryllium dust and fumes into the lungs. People with exposure can develop a response to beryllium similar to an allergy which can lead to scars in the lungs and breathing problems. The goal of this study is to understand how certain white blood cells called macrophages function in the development of CBD. By collecting lung and blood samples from healthy adults, our researchers can learn more about the cells involved in the development of scarring lung diseases and ultimately target new treatment therapies. Enrollment Active Clinical Trials Currently Recruiting Who Can Participate Healthy, nonsmoking adults with no prior history of respiratory or autoimmune disease who are able to undergo a blood draw and a bronchoscopy. Age: 18-80 Gender: Any Gender Estimated Time Commitment 5 hours over 2 visits During the first visit, participants give consent and receive physical exam. Second visit includes bronchoalveolar lavage and blood draw. The second visit will last approximately four hours. × Payments are intended to compensate the participant for their time and effort during the study. Payments are typically given to the participant at the end of each completed study visit. Reimbursements are intended to compensate the participant for travel-related expenses. They must be approved by the study staff and require you to turn in receipts. Travel reimbursement will vary from study to study. Payment & Reimbursement Payment: Provided Travel Reimbursement: Not Available Trial Contact For more information, contact: Peggy Mroz 303.398.1730 Request More Information Trial Location National Jewish Main Campus, Denver, CO Trial Sponsors National Institutes of Health Principal Investigators Li Li, MD, PhD + × Li Li, MD, PhD Division of Environmental & Occupational Health Sciences Department of Medicine View Full Profile Make an Appoinment Co-Investigators Lisa Maier, MD, MSPH, FCCP + × Lisa Maier, MD, MSPH, FCCP Professor Director, Division of Env & Occ Health Science Core Clinical Lab Chief, Division of Environmental & Occupational Health Sciences Department of Medicine View Full Profile Patient Rating 4.9 out of 5 stars Make an Appoinment Request More Information By completing this form, you agree to learn more about this study and see if you qualify. First Name:* Last Name:* Email Address:* Phone:* I would also like to receive periodic emails with health information, news and clinical research updates from National Jewish Health: YesNo
Trial Objective Chronic beryllium disease (CBD) is caused by inhaling beryllium dust and fumes into the lungs. People with exposure can develop a response to beryllium similar to an allergy which can lead to scars in the lungs and breathing problems. The goal of this study is to understand how certain white blood cells called macrophages function in the development of CBD. By collecting lung and blood samples from healthy adults, our researchers can learn more about the cells involved in the development of scarring lung diseases and ultimately target new treatment therapies.